Board of Directors
Kenneth M. Bate
Kenneth M. Bate has served as a director since December 2007. He is currently an independent consultant. Previously, Mr. Bate was the president and chief executive officer of Archemix Corp., a position he held from April 2009 through December 2011. From 2006 to April 2009, he served in various positions at NitroMed, Inc., most recently as president and chief executive officer. From 2002 to 2005, Mr. Bate served as head of commercial operations and chief financial officer at Millennium Pharmaceuticals, Inc. Prior to joining Millennium Pharmaceuticals, Inc., Mr. Bate co-founded JSB Partners, LLC, a banking and advisory services firm for biopharmaceutical and life sciences companies. From 1990 to 1996, he was with Biogen, Inc. (now Biogen Idec Inc.) first as their chief financial officer and then as head of the commercial organization responsible for launching its multiple sclerosis business. Mr. Bate currently serves as chairman of the board of Cubist Pharmaceuticals, Inc., and on the board of BioMarin Pharmaceutical, Inc. During the last five years, Mr. Bate has served as a director of NitroMed, Inc., Archemix Corp., TransMedics, Inc. and Coley Pharmaceutical Group, Inc. He holds a B.A. in chemistry from Williams College and an M.B.A. from The Wharton School of the University of Pennsylvania. We believe Mr. Bate’s qualifications to serve on our board of directors include his operating, finance, commercial, transactional and senior management experience in the industry, such as his experience as chief executive officer of Archemix Corp. and NitroMed, Inc., and head of commercial operations and chief financial officer at Millennium Pharmaceuticals, Inc., as well as his experience serving on the board of directors of other public companies in the life sciences industry, such as Cubist Pharmaceuticals, Inc. and BioMarin Pharmaceuticals, Inc.
Anthony B. Evnin, Ph.D.
Anthony B. Evnin, Ph.D. has been a Partner at Venrock, a venture capital firm, since 1975. Dr. Evnin currently serves on the Board of Directors of AVEO Pharmaceuticals and Infinity Pharmaceuticals as well as on the Boards of two private companies, Constellation Pharmaceuticals and Juno Therapeutics. He is a Trustee of The Rockefeller University, a Member of the Boards of Overseers and Managers of Memorial Sloan-Kettering Cancer Center, a Trustee of The Jackson Laboratory, a Director of the New York Genome Center, a Member of the Board of Directors of the Albert and Mary Lasker Foundation, and a Trustee Emeritus of Princeton University. Dr. Evnin received an A.B. in chemistry from Princeton University and a Ph.D. in chemistry from the Massachusetts Institute of Technology.
Henri A. Termeer
LEAD OUTSIDE DIRECTOR
Henri A. Termeer has served as a director of AVEO since April 2011 and is Chairman of the Board. He served as chairman, president and chief executive officer of Genzyme Corporation for nearly three decades. Mr. Termeer was appointed president of Genzyme in 1983, two years after the company's founding. He became its chief executive officer in 1985 and chairman in 1988. He retired from Genzyme in June 2011 following the acquisition of Genzyme by Sanofi in a transaction valued at more than $20 billion. In 2008, he was appointed to Massachusetts Governor Deval Patrick’s Council of Economic Advisors, and he is a co-chair of the Leadership Council of the Massachusetts Life Sciences Collaborative. Mr. Termeer is also Chairman Emeritus of the New England Healthcare Institute, a nonprofit, applied research health policy organization he was instrumental in founding. Mr. Termeer was Chairman of the Federal Reserve Bank of Boston’s Board of Directors from 2010-2011. He is a board member of ABIOMED Inc., Verastem, Inc. and Medical Simulation. Mr. Termeer is a Board member of Massachusetts Institute of Technology Corporation and serves on its Executive Committee, is a director of Massachusetts General Hospital, a Board member of Partners HealthCare and a member of the Board of Fellows of Harvard Medical School. He served on the Board of Directors of the Pharmaceutical Research and Manufacturers of America. Mr. Termeer studied economics at the Economische Hogeschool (Erasmus University, The Netherlands) and earned an M.B.A from the Darden School at the University of Virginia.
Robert C. Young, M.D.
Robert C. Young, M.D. has served as a director since July 2009. Dr. Young is president of RCY Medicine, a consulting service focused on cancer center productivity, health care quality and health policy which he founded in July 2009. From 2007 to 2009 he served as chancellor of Fox Chase Cancer Center in Philadelphia and as president and chief executive officer from 1989 to 2007. Dr. Young is a past-president of the American Society of Clinical Oncology, the American Cancer Society and the International Gynecologic Cancer Society and past Chairman of the Board of Scientific Advisors of the National Cancer Institute. He holds a B.Sc. in zoology from Ohio State University and an M.D. from Cornell University Medical College and is Board certified in Internal Medicine, Hematology and Medical Oncology.
Michael P. Bailey
PRESIDENT AND CEO
Michael P. Bailey serves as president and chief executive officer of AVEO and a member of the company’s board of directors, bringing more than 20 years of experience in the pharmaceutical industry to the company. He joined AVEO in 2010 as the company’s chief commercial officer, was named chief business officer in 2013 and assumed his current roles in January 2015. Mr. Bailey joined AVEO from Synta Pharmaceuticals, where he served as senior vice president, business development, and chief commercial officer since 2008. Prior to joining Synta, Mr. Bailey led ImClone Systems' (now Eli Lilly) Worldwide Commercial Organization. During his nine year tenure at ImClone, he was responsible for commercial aspects of the planning and launch of ERBITUX® (cetuximab) across multiple oncology indications, as well as new product planning for the ImClone development portfolio, which included CYRAMZA® (ramucirumab) and necitumumab. In addition, Mr. Bailey was a key member of the strategic leadership committees for ImClone and its North American and worldwide partnerships. Prior to joining ImClone, Mr. Bailey managed the cardiovascular development portfolio at Genentech, Inc., and was a key member of their global commercial partnership teams. Mr. Bailey started his career in the pharmaceutical industry as part of SmithKline Beecham's Executive Marketing Development Program, where he held a variety of commercial roles, including sales, strategic planning, and product management. Mr. Bailey received a B.S. in psychology from St. Lawrence University and an M.B.A. in international marketing from the Mendoza College of Business at University of Notre Dame.